Primary Analysis of Phase 2 Results for Cemiplimab in Patients With Metastatic Basal Cell Carcinoma Who Progressed on or Were Intolerant to Hedgehog Inhibitors. J of Skin 2023, 7 (2), s177. https://doi.org/10.25251/skin.7.supp.177.